NAIROBI, Kenya- Kenya has taken a major step in the fight against HIV with the introduction of Lenacapavir, a new long-acting injectable medicine used for HIV prevention.
According to Health Cabinet Secretary Aden Duale, Kenya currently has an HIV prevalence of about 3.7 percent, with approximately 1.34 million people on anti-retroviral treatment.
While progress has been made over the years, new infections remain a concern, especially among young people, Health Cabinet Secretary Aden Duale said in a statement on Wednesday.
In fact, 41 percent of new HIV infections occur among people below 24 years, highlighting the urgent need for new and more practical prevention options.
What is Lenacapavir?
Lenacapavir is a long-acting form of pre-exposure prophylaxis (PrEP).
Duale explained that PrEP is a medicine taken by HIV-negative individuals to reduce their risk of getting infected.
Unlike daily HIV prevention pills, Lenacapavir is given as an injection only twice a year, offering six months of protection per dose.
This makes it easier for people who struggle with taking daily medication consistently.
It is important to clarify that Lenacapavir is not a vaccine and not a cure for HIV. It is strictly a prevention tool for people who are HIV-negative.
Those already living with HIV must continue their lifelong treatment.
Why Is This a Big Deal for Kenya?
In July 2025, Kenya was selected among the first nine countries globally — and the first in East Africa — to introduce Lenacapavir. Other selected countries include Eswatini, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia and Zimbabwe.
This selection reflects Kenya’s readiness to adopt modern, science-based prevention tools. Lenacapavir was approved by the United States Food and Drug Administration in June 2025 and later endorsed by the World Health Organisation in updated guidelines released in July 2025.
In January 2026, Kenya’s Pharmacy and Poisons Board approved both the tablet and injectable forms after a detailed scientific review.
How Does It Work?
Lenacapavir works by blocking critical stages of the HIV life cycle. In simple terms, it prevents the virus from establishing infection in the body if a person is exposed.
Its biggest advantage is convenience and discretion. Since it is administered only twice a year, it reduces the burden of daily pill-taking and may improve adherence — especially among young people and high-risk groups.
How Will It Be Rolled Out?
Kenya has received 21,000 starter doses for the initial rollout. An additional 12,000 continuation doses are expected by April to ensure uninterrupted treatment for those who begin the injections. The United States Government has also committed 25,000 additional doses.
The first phase begins in early March across 15 counties, including Nairobi, Mombasa, Kisumu, Homa Bay, Nakuru, Machakos, Kilifi and others. Nationwide access will follow in phases.
The current batch has been funded through the Global Fund at a negotiated cost of Sh7,800 per patient per year.
